MI Gateway Volume 13, Issue 1 (March 2019)

Volume 13, Issue 1

MI Gateway is a quarterly member information service published under the direction of the Center for Molecular Imaging Innovation and Translation leadership and SNMMI.
Volume 13 • Issue 1 • 2019-1

 In This Issue

 MI Gateway

Editorial Board

Walter Akers, DVM, PhD
Cathy S. Cutler, PhD
Leslie Flynt, MD
Anthony Giamis, PhD
Catalin I. Grigore, MIS, NMAA, CNMT
Alexander L. Klibanov, PhD

Issue Editor: Cathy S. Cutler, PhD

©2019 by SNMMI


Sn-117m: A New Therapeutic and Diagnostic Tool for Canine Joint Inflammation

Nigel R. Stevenson, PhD, and John M. Donecker, VMD, MS; Convetra, Inc.

Radiosynoviorthesis in Clinical Practice

The term radiosynoviorthesis (RSO) was introduced in Europe in the 1960s by Florian Delbarre to describe therapeutically active irradiation of the synovial lining.1 Rheumatologists administered a colloid embedded with a radionuclide (i.e., a radiocolloid) of yttrium-90 (90Y) into the articular space. Using this process, the colloidal particles are phagocytized by macrophages in the synovial lining, after which they emit therapeutically active irradiation of the synovial tissue until the radionuclide decays to its stable state. The number of inflammatory cells causing synovitis is reduced, and inflamed tissue may be replaced with a fibrotic synovial membrane, with a corresponding alleviation of pain and improvement in function.2,3

A key aspect of RSO is the choice of a radionuclide. Three radionuclides are widely used in clinical practice to treat synovitis: 90Y, rhenium-186 (186Re), and erbium-169 (169Er), all of which are artificially produced in a nuclear reactor.2-4 In the case of RSO treatment, the radionuclide emits radiation that penetrates the outermost layer of the synovial membrane, where it produces energy of sufficient duration and intensity to achieve apoptosis and ablative necrosis of the inflamed cells. For this to occur, the radionuclide must have an adequate half-life (t½), a selective tissue penetration range approximating the synovial thickness, and sufficient energy for therapeutic effect.

  Figure 1. The diagram compares the radiation dose range of conversion electrons emitted by 117mSn (300 mm, green zone) with beta-radiation emitted by radionuclides such as 90Y, 186Re, and 169Er (up to 11,000 mm, blue zone). The ultra-narrow, discrete radiation range of 117mSn enables more precise dosimetry and allows avoidance of adverse effects on adjacent tissues that can occur with beta-emitting radionuclides. 

As 90Y, 186Re, and 169Er decay, they emit radiation in the form of beta particles with a relatively wide tissue penetration range (Figure 1). While these radionuclides are therapeutically useful and have been evaluated in large clinical trials,2 their physical properties are not necessarily ideal for RSO. For example, 90Y emits beta radiation that has a relatively wide range of soft tissue penetration, which risks irradiation of adjacent non-synovial tissue. 186Re and 90Y have short half-lives (2.7 and 3.7 days respectively), which creates storage and logistical limitations, and may not consistently deliver sufficient irradiation at the synovial target site.5  169Er lacks diagnostic emissions, which makes traceability a potential issue.

Tin-117m: A Novel Radionuclide

Tin-117m (117mSn) is a unique radionuclide without the disadvantages of high-energy beta-emitting radionuclides (Table 1 compares physical properties of 117mSn with other therapeutic radionuclides).6 As such,117mSn is particularly well suited for RSO, including in dogs and horses. Instead of high-energy beta particles with a wide tissue penetration range (50–5,000 mm), 117mSn emits abundant conversion electrons, low-energy particles with a short, relatively non-diminishing penetration range of approximately 300 mm in tissue (Figure 1).


 Table 1 – Comparison of radionuclides commonly used for radiosynoviorthesis with tin-117m




Half-life (days)


Maximum energy (keV)


Mean tissue penetration (mm)


Maximum tissue penetration (mm)


Therapeutic emission


Diagnostic emission (keV)














gamma (137)













conversion electrons

gamma (159)


117mSn has a t½ of nearly 14 days, providing an ideal duration of effect spanning several half-lives to achieve therapeutic results and to enable short-term stability during storage and handling. To illustrate, Figure 2 shows >99% dose retention in the joint of a dog 3 days following intra-articular injection (Figure 3) with homogenous 117mSn colloid (Synovetin OA™).7 No other radionuclide with the theranostic and physical properties of 117mSn exists.8


Figure 2. Scintigraphy of a Synovetin OA-injected canine elbow shows high dose retention of the homogenous colloid with minimal uptake in the draining lymph node 3 days after administration. Retention at this time point was measured at >99% in synovial tissue, indicating a continuous therapeutic effect consistent with the 14-day half-life of 117mSn. (Image courtesy of Jimmy Lattimer, DVM.)


Figure 3. Experimental intra-articular injection of Synovetin OA into the caudolateral aspect of a canine elbow, positioned at 45-degree flexion, between the lateral condyle of the humerus and the triceps tendon. Following injection the joint is put through a range of motion to disperse the radiocolloid throughout the synovial surface. (Photo courtesy of Cynthia Doerr, MD.)

Due to its unique therapeutic and diagnostic (theranostic) properties as a conversion electron- and gamma-emitter with an optimal t1/2, 117mSn has attracted interest as a radiopharmaceutical and also now as a medical device in the colloid form. Favorable results were reported in Phase I and II clinical trials where 117mSn was used to treat metastatic bone pain in human patients.9-11 Investigators noted the value of the gamma emission component of 117mSn, which provides an objective basis for diagnostic monitoring, disease staging, dosage estimates, and assessing response to therapy.11,12

Synovetin OA: A homogenous colloid of 117mSn

Convetra Inc. has developed a patented preparation of 117mSn specifically for RSO and other potential applications in veterinary and human medicine. 117mSn is manufactured using methods that produce yields sufficient to be scaled up for manufacturing therapeutic dosages in commercial quantities.8 The 117mSn radionuclide is combined with a homogenous colloid to form the final injectable product, Synovetin OA.8 The radionuclide particles are small enough to be phagocytized by synovial macrophages but large enough to avoid leakage outside the joint prior to phagocytosis. In situ retention of the Synovetin OA in laboratory animals has been measured out to five t½ (i.e., 68 days), a duration sufficient for therapeutic efficacy. Synovetin OA has demonstrated safety and efficacy following RSO of experimental OA in rats and dogs. In particular, safety trials in 100 canine elbow joints of 75 dogs has shown no clinically significant device-related safety problems following intra-articular injections. Also, clinical effectiveness following intra-articular injection in naturally occurring osteoarthritic elbows has had long lasting efficacy—often for 12 months.

Synovetin OA will be commercially available in 2019. The next application for this product is the treatment of human arthritides. This will be accomplished through clinical trials in Canada (where radiosynoviorthesis experience exits) beginning in mid-2019.

Clinically Important Features of 117mSn

Several features of 117mSn make it well suited for RSO and an improvement over other therapeutic radionuclides:

  • Localized administration: Intra-articular dosing is suitable for outpatient use.

  • Non-beta emitter: Avoids high-energy irradiation of non-synovial tissue, extra-articular diffusion, or systemic distribution.

  • Emits low-energy conversion electrons: Minimizes potential for synovial scarring and eliminates collateral tissue damage.

  • Gamma radiation emitter: Gamma energy of 159 keV is suitable for diagnostic imaging and is similar to the commonly used diagnostic radionuclide technetium-99m (140 keV).

  • Half-life of 14 days: Enables sufficient tissue retention for therapeutic efficacy and a shelf life of several weeks.

  • Practical handling characteristics: Ease of handling, hospital containment and shipping using standard radiological safety and packaging practices.


  1. Delbarre F, Cayla J, Menkes C, et al. Synoviorthesis with radioisotopes. Presse Med. 1968;76:1045-1050.
  2. Kampen WU, Voth M, Pinkert J, et al. Therapeutic status of radiosynoviorthesis of the knee with yttrium [90Y] colloid in rheumatoid arthritis and related indications. Rheumatology. 2007;46:16-24. 
  3. Karavida N, Notopoulos A. Radiation synovectomy: an effective alternative treatment for inflamed small joints. Hippokratia. 2010;14:22-27.
  4. Klett R, Lange U, Haas H, et al. Radiosynoviorthesis of medium-sized joints with rhenium-186-sulfide colloid: a review of the literature. Rheumatology. 2007;46:1531-1537.
  5. Silva M, Luck JV Jr, Llinas A. Chronic hemophilic synovitis: The role of radiosynovectomy. Treatment Hemophilia. 2004;33:1-10.
  6. Brenner W. Radionuclide joint therapy. In: Eary JF, Brenner W, eds. Nuclear Medicine Therapy. New York: Informa Healthcare; 2007:21-44.
  7. Stevenson N, Lattimer J, Selting K, et al. Abstract S6-03: Homogeneous Tin-117m colloid - A novel radiosynovectomy agent. World J Nucl Med. 2015;14(Suppl 1):S15–S68.
  8. Stevenson NR, St. George G, Simon J, et al. Methods of producing high specific activity Sn-117m with commercial cyclotrons. J Radioanal Nucl Chem. 2015;305:99-108.
  9. Atkins HL, Mausner LF, Srivastava SC, et al. Tin-117m(4+)-DTPA for palliation of pain from osseous metastases: a pilot study. J Nucl Med. 1995;36:725-729.
  10. Krishnamurthy GT, Swailem FM, Srivastava SC, et al. Tin-117m(4+)DTPA: pharmacokinetics and imaging characteristics in patients with metastatic bone pain. J Nucl Med. 1997;38:230-237.
  11. Srivastava SC, Atkins HL, Krishnamurthy GT, et al. Treatment of metastatic bone pain with tin-117m Stannic diethylenetriaminepentaacetic acid: a phase I/II clinical study. Clin Cancer Res. 1998;4:61-68.
  12. Srivastava SC. The role of electron-emitting radiopharmaceuticals in the palliative treatment of metastatic bone pain and for radiosynovectomy: applications of conversion electron emitter Tin-117m. Brazilian Arch Biol Technol. 2007;50:49-62.


Houston, We Have a Problem: The Mo-99/Tc-99m Shortage Experience at MD Anderson

Manisha A. Patel, BS, RT(N)(PET)(CT), The Univeristy of Texas, M.D. Anderson Cancer Center, Clinical Nuclear Medicine

It was the best of times, it was the worst of times. The nuclear medicine clinic was thriving, but the most commonly used radiotracer, technetium-99m (99mTc) was in short supply. The shortage of this tracer was due to the shortage of its source, molybdenum-99 (99Mo). While an isotope shortage is nothing new to us in nuclear medicine, we have a few tricks up our sleeves to make the best of things out of the worst of times.

As one would imagine, at MD Anderson Cancer Center the bulk of our 99mTc is used for cancer imaging, most commonly in the form of bone scans to assess for bony metastatic disease. We also perform plenty of lymphoscintigraphy studies for sentinel node identification in breast cancer and melanoma, parathyroid scintigraphy, and breast-specific gamma imaging. We throw in a few myocardial perfusion studies, renal scans, HIDA, GI bleed, and gastric emptying studies, as well as a few ventilation/perfusion and ventriculography scans, etc., here and there. Thus, we use an average of about one curie of 99mTc per day.

We do not have an on-site 99Mo/99mTc generator; therefore, our doses are routinely delivered in bulk each morning and on an as-needed basis throughout the day. As the 99mTc shortage became reality, our vendors were able to provide only unit doses—no bulk doses. Input from our vendors was helpful in that they suggested moving the majority of patients to certain days of the week when we could take the most advantage of high activity in their 99Mo generators.

The Game Plan

At our institution, the study affected most by the 99mTc  shortage was the bone scan. In order to continue to provide the best possible care for our patients and to keep our clinic running smoothly, we tackled this problem by reducing the bone scan dose from 20 mCi per patient to 10 mCi per patient, and to optimize imaging we reduced scan speed from 12 cm/sec to 9 cm/sec. This technique worked very well for our clinic and produced images well worthy of diagnostics.

The next highest concern related to myocardial perfusion studies, as they often require higher doses than other studies. To address this problem, we performed dual tracer studies using thallium-201, with stress first, immediate imaging, and rest next, four hours later.

For lymphoscintigraphy we did not receive bulk technetium for filtered sulfur colloid as usual, but we managed to survive on unit dose delivery.


For a little background on the shortage: there currently are no domestic producers of 99Mo in the United States. The world relies on seven major reactors for 95 percent of the global 99Mo supply for medical use. There is an eighth reactor undergoing clearance, but it has not yet received approval for production (Figure 1).

Figure 1: Reactors currently supplying the world with medical isotopes. Seven reactors provide 95% of the world’s supply of 99Mo. HFR and BR-2 align maintenance schedules (blue circle). OPAL and SAFARI-1 align maintenance schedules (red circle).

Generally, the Association of Imaging Producers and Equipment Suppliers (AIPES) coordinates maintenance schedules in order to avoid lapses in isotope production. For example, OPAL and SAFARI-1 coordinate maintenance schedules, as do HFR and BR-2, so that the others may continue to provide the world supply while these work on routine maintenance. The Security of Supply Working Group of AIPES reviews all reactor schedules and identifies where there are concerns over lapses in 99Mo availability, and schedules are then adjusted to optimize reactor up and down times.

Unforeseen circumstances nonetheless continue to remind us of the need for more robust sources of medical isotopes, both at home and abroad. As an example, a recent shortage in reactor-produced medical isotopes was driven by an unscheduled delay in operations at HFR, combined with a regularly scheduled maintenance shutdown of OPAL as well as the prolonged approval process for NTP. This sequence of events turned into a perfect storm—a global iodine-131 and 99Mo (and thus a 99mTc) shortage.

Although we have now returned to regularly scheduled programming, it is of great importance that we share our experiences in order to learn from each other how to make the best of things in the worst of times.


Dallar A. (2018, November 5). ‘Everyone will feel the pinch’: Nuclear imaging labs brace for 99mTc  shortage. Cardiovascular Business. Retrieved from https://www.cardiovascularbusiness.com/topics/cardiovascular-imaging/nuclear-imaging-labs-brace-99mTc -shortage.

Jawerth N. (2017, September 22) Supplies of Key Medical Isotopes Stable, but Vulnerabilities Remain. International Atomic Energy Agency. Retrieved from https://www.iaea.org/newscenter/news/supplies-of-key-medical-isotopes-stable-but-vulnerabilities-remain.

Ponsard B, Goldman I. (2018, July 9) Cessation of Mo-99 Production Activities by NTP Radioisotopes Ltd. (NTP) Update ANSTO Press Release – OPAL reactor – Update. Retrieved from http://www.aipes-eeig.org/spip.php?article65  

Tollefson J. (2018, November 30) Reactor shutdown threatens world’s medical-isotope supply. Nature News. Retrieved from https://www.nature.com/news/reactor-shutdown-threatens-world-s-medical-isotope-supply-1.20577.

Van de Wiel A, Menno B. Medical Applications of a Nuclear Reactor. Am J Intern Med. (2019) 7(1):1-4.

National Academies of Sciences, Engineering Medicine. Molybdenum-99 for Medical Imaging. The National Academies Press, 2016.

Society of Nuclear Medicine and Molecular Imaging. (2018, November 19) SNMMI Addresses Mo-99 Isotope Shortage. Retrieved from http://www.snmmi.org/NewsPublications/NewsDetail.aspx?ItemNumber=30311.



Call for Nominations

2019 Center for Molecular Imaging Innovation and Translation (CMIIT) Board of Directors Call for Nominations

The CMIIT Nominating Committee would like to announce the call for nominations for the 2019 CMIIT Board of Directors election. The Nominating Committee has the task of preparing a slate of candidates for TWO at-large board members, one of which is a technologist position.

We invite the CMIIT membership to nominate candidates for these positions. Elected individuals will begin their three-year terms at the conclusion of the SNMMI Annual Meeting in June 2019. CMIIT board members will be tasked with helping the Center move forward with new goals and initiatives and should plan on attending all CMIIT board meetings (2–3 per year) and conference calls. This is a great opportunity to get involved in CMIIT activities!


  • Nominations should be forwarded to K. Malaika Walton, SNMMI Associate Director of Governance, at mwalton@snmmi.org by March 6, 2019
  • Nominations must include the nominee’s one-paragraph statement of interest in running for the CMIIT board (platform statement), the nominee’s CV, and the nominee’s photo.
  • Nominees must be members of CMIIT.
  • CMIIT encourages self-nominations, as well as nominations of technologist members and members with expertise in non-nuclear molecular imaging.

Please help us by nominating creative leaders who will continue to build CMIIT on its existing strong foundation.

Annual Meeting

Join CMIIT at the 2019 SNMMI Annual Meeting (June 22-25). CMIIT will be hosting sessions on the following topics:

Categorical: Saturday, June 22, 7:30 am-3:00 pm

PET Imaging of Autoimmunity and Immune Checkpoint Inhibition Efficacy (co-sponsored with Correlative Imaging Council, PET Center of Excellence and Radiopharmaceuticals Council), organized by Delphine Chen, MD; David Dick, PhD; Katherine Zukotynski, BASc, MD, FRCPC; and Twyla Bartel, DO, MBA, FACNM

CE Sessions

Saturday, June 22, 1:30 – 3:00pm     CE02: Target Identification, organized by Kimberly Kelly, PhD, and Ali Azhdarinia, PhD

Sunday, June 23, 3:00 – 4:30pm       CE23: Molecular Imaging in Drug Development, organized by Ali Azhdarinia, PhD, and Thomas Ng, MD, PhD

Monday, June 24, 10:00 – 11:30am   CE37: Cancer Immunotherapy: Current Status and Future Outlook, organized by Hossein Jadvar, MD, PhD, MPH, MBA, FACNM, FSNMMI

Monday, June 24, 3:00 – 4:30pm CE51: US Regulatory Pathways for Diagnostic and Therapy Radiopharmaceuticals, organized by Delphine Chen, MD, Bonnie Clarke, and Cathy Cutler, PhD

Tuesday, June 25, 3:00 – 4:30pm CE86: AI for Data Sciences, organized by Georges El Fakhri, PhD, FSNMMI, and Kimberly Kelly, PhD


CMIIT will also host a Young Investigators Award session and three Emerging Technologies (non-CE) sessions during the Annual Meeting.

Get more information and register: http://www.snmmi.org/AM2019


MI in the Literature

Each month, the CMIIT Editorial Board selects some of the top molecular imaging research papers from all papers indexed by PubMed. Below are links to these papers.

Analysis of Progress and Challenges of EGFR-Targeted Molecular Imaging in Cancer With a Focus on Affibody Molecules.

Chen W, Shen B, Sun X. PMID: 30799684.

Anti-EGF Receptor Aptamer-Guided Co-Delivery of Anti-Cancer siRNAs and Quantum Dots for Theranostics of Triple-Negative Breast Cancer.
Kim MW, Jeong HY, Kang rSJ, Jeong IH, Choi MJ, You YM, Im CS, Song IH, Lee TS, Lee JS, Lee A, Park YS. PMID: 30809593.

Applications of SNAP-tag technology in skin cancer therapy.
Padayachee ER, Adeola H2, Van Wyk JC, Nsole Biteghe FA, Chetty S, Khumalo NP, Barth S. PMID: 30809593.

The Challenge to Search for New Nervous System Disease Biomarker Candidates: The Opportunity to Use the Proteogenomics Approach.
Nery TGM, Silva EM, Tavares R, Passetti F. PMID: 30554402.

Confirmation of Specific Binding of the 18-kDa Translocator Protein (TSPO) Radioligand [18F]GE-180: a Blocking Study Using XBD173 in Multiple Sclerosis Normal Appearing White and Grey Matter.
Sridharan S, Raffel J, Nandoskar A, Record C, Brooks DJ, Owen D, Sharp D, Muraro PA, Gunn R, Nicholas R. PMID: 30796709.

Discovery of N-(4-[18F]fluoro-5-methylpyridin-2-yl)isoquinolin-6-amine (JNJ-64326067), a new promising tau positron emission tomography (PET) imaging tracer.
Rombouts FJR, Declercq L, Andrés JI, Bottelbergs A, Chen L, Iturrino L, Leenaerts JE, Mariën J, Song F, Wintmolders C, Wuyts SL, Xia C, Te Riele P, Bormans GM, Vandenberghe R, Kolb H, Moechars D. PMID: 30810314

Improved radiosynthesis and preliminary in vivo evaluation of the 11C-labeled tetrazine [11C]AE-1 for pretargeted PET imaging.
Stéen EJL, Jørgensen JT, Petersen IN, Nørregaard K, Lehel S, Shalgunov V, Birke A, Edem PE, L'Estrade ET, Hansen HD, Villadsen J, Erlandsson M, Ohlsson T, Yazdani A, Valliant JF, Kristensen JL, Barz M, Knudsen GM, Kjær A, Herth MM. PMID: 30795854

Interactions of gold and silica nanoparticles with plasma membranes get distinguished by the van der Waals forces: Implications for drug delivery, imaging, and theranostics.
Jing H, Sinha S, Sachar HS, Das S. PMID: 3079806.

Potential of Sodium MRI as a Biomarker for Neurodegeneration and Neuroinflammation in Multiple Sclerosis.
Huhn K, Engelhorn T, Linker RA, Nagel AM. PMID: 30804885

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction.
Membreno R, Cook BE, Zeglis BM. PMID: 30774125

Radioguided lung lesion localization: introducing a fluoroscopy system in a SPECT/CT scan.
Durmo R, Lechiara M, Benetti D, Rodella C, Camoni L, Albano D, Bertagna F, Giubbini R. PMID: 30789851.

Relationship between inflammation and progression of an abdominal aortic aneurysm in a rabbit model based on 18F-FDG PET/CT imaging.
Nie MX, Zhang XH, Yan YF, Zhao QM. PMID: 29673292.

SPECT/CT imaging of chemotherapy-induced tumor apoptosis using (99m)Tc-labeled dendrimer-entrapped gold nanoparticles.
Xing Y, Zhu J, Zhao L, Xiong Z, Li Y, Wu S, Chand G, Shi X, Zhao J. PMID: 29869521.


MI in the News

MI Gateway presents a sampling of research and news of interest to the community of molecular imaging scientists.

Scientists use optical imaging to find deep cancers in their earliest stages

MIT researchers have developed a near-infrared imaging technique that can detect tumors deep in internal tissue before the cancer grows beyond a few hundred cells. A co-lead author of the preclinical study describing the work, Angela Belcher, PhD, told MIT News the system can track a 0.1-millimeter fluorescent probe to a tissue depth of 8 centimeters— “far deeper than any existing biomedical optical imaging technique.”

New optical imaging system could be deployed to find tiny tumors
MIT News
MIT researchers have now developed an imaging system, named “DOLPHIN,” which could enable them to find tiny tumors, as small as a couple of hundred cells, deep within the body. The researchers used their imaging system, which relies on near-infrared light, to track a 0.1-millimeter fluorescent probe through the digestive tract of a living mouse. They also showed that they can detect a signal to a tissue depth of 8 centimeters, far deeper than any existing biomedical optical imaging technique.

Improving molecular imaging using a deep learning approach
Science Daily
Generating comprehensive molecular images of organs and tumors in living organisms can be performed at ultra-fast speed using a new deep learning approach to image reconstruction developed by researchers at Rensselaer Polytechnic Institute. The research team's new technique has the potential to vastly improve the quality and speed of imaging in live subjects.

Endoscopy at the Tip of a Fiber
Biophotonics World
Researchers from Germany and the United Kingdom have developed an endoscopy system for deep-brain in vivo high-resolution fluorescence imaging at the tip of a multimode optical fiber. The imaging system uses new methods for holographic control of light propagation in complex media, such as the brain, to increase imaging speed and improve image quality. The researchers successfully demonstrated their minimally invasive imaging system on deep-brain regions in live mouse models.

Portable fluorometer detects breast cancer cells
A portable fluorometer designed to detect fluorescence emitted from labelled cancer cells has been successfully validated by researchers at the University of Saskatchewan. The device — constructed of inexpensive, off-the-shelf products — is targeted at researchers in hospitals and laboratories for use as an alternative to expensive fluorescence imaging.

Cell Metabolism and Cancer
Cancer Research
It’s almost 100 years since Otto Warburg’s observation that cancer cells metabolize glucose in a manner that is distinct from that of cells in normal tissues. In the years since, significant effort and resource has focused on understanding cancer-specific metabolic changes. Today, attention is also turning to the metabolic interaction between a tumor and its host. With advances in metabolomics and molecular imaging technologies, can the cancer metabolism field finally reach its full potential?

Shaping light lets 2D microscopes capture 4D data
Rice University researchers have developed a method to let a microscope capture 3D spatial information along with the fourth dimension, molecular movement over time. This, they say, will help scientists who study dynamic processes view where molecules of interest are located and how fast they move -- for example, within living cells.

Researchers develop non-invasive imaging tech to assess cardiovascular risk
Verdict Medical Devises
Researchers in Switzerland have developed a non-invasive technique for imaging the carotid artery, which could provide an earlier, more accurate assessment of cardiovascular disease risk than other imaging methods. The new cardiovascular imaging technique is called volumetric multi-spectral optoacoustic tomography (vMSOT).

New method uses fluorescence to identify disease-causing forms of proteins
A new method uses fluorescence to detect potentially disease-causing forms of proteins as they unravel due to stress or mutations. A team of researchers from Penn State and the University of Washington reengineered a fluorescent compound and developed a method to simultaneously light up two different proteins as they misfold and aggregate inside a living cell, highlighting forms that likely play a role in several neurodegenerative diseases including Alzheimer's and Parkinson's.

New findings could provide novel approach to target and destroy cancer cells
An unexpected finding in pre-clinical platelet studies by Baker Institute researchers could provide a novel approach to targeting and destroying difficult-to-treat cancer cells, providing new therapeutic options for a range of cancers. This latest finding was discovered while studying activated platelets in the setting of heart disease and may now prove useful for delivering targeted treatment to cancer cells without major side effects.

Optical imaging checks tumour margins during breast cancer surgery
For patients with early-stage breast cancer, breast-conservation surgery is a preferred option to mastectomy. However, if histopathological analysis reveals that the malignant tissue was not totally removed, the patient will need to undergo re-excision days later. A tool that could accurately assess tumour margins during breast-conserving surgery would help surgeons to totally remove the tumour in the initial procedure and reduce re-excision rates, which are currently up to 30%.


Calendar of Events

11th International Symposium on Targeted-Alpha-Therapy
April 1 – 5, 2019
Ottawa, Ontario, Canada

BNMS Spring Meeting 2019
April 1 – 3, 2019
Oxford, United Kingdom

SNMMI-NECTS (New England Chapter Meeting
April 5 – 6, 2019
Windsor, CT

PSWTC Spring Meeting 2019
April 6, 2019
Chandler, AZ

49th Annual Spring MECSNM
April 12 – 14, 2019
Gettysburg, PA

SNMMI 2019 Annual Meeting
June 22 – 25, 2019
Anaheim, CA